ARROW trial, Genentech, NSCLC, pralsetinib
Pralsetinib is approved by the FDA for non-small cell lung cancer with RET gene fusions
August 2023: Pralsetinib (Gavreto, Genentech, Inc.) was given regular approval by the Food and Drug Administration for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), as determined by an FDA..
CD20, Columvi, DLBCL, Genentech
Glofitamab-gxbm is approved by FDA for selected relapsed or refractory large B-cell lymphomas
July 2023: The Food and Drug Administration gave accelerated approval to glofitamab-gxbm (Columvi, Genentech, Inc.) for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell ly..
Genentech, Lunsumio, mosunetuzumab-axgb, refractory follicular lymphoma
Mosunetuzumab-axgb is granted accelerated approval for relapsed or refractory follicular lymphoma
Jan 2023: Mosunetuzumab-axgb (Lunsumio, Genentech, Inc.), a bispecific CD20-directed CD3 T-cell engager for adult patients with relapsed or refractory follicular lymphoma (FL) following two or more rounds of systemic therapy, rece..
alveolar soft part sarcoma, Atezolizumab, central nervous system, Genentech, Tecentriq
Atezolizumab is approved by FDA for alveolar soft tissue sarcoma
Dec 2022: Atezolizumab (Tecentriq, Genentech, Inc.) has been approved by the Food and Drug Administration (FDA) for adult and paediatric patients with unresectable or metastatic alveolar soft part sarcoma who are 2 years of a..
Burkitt lymphoma, Burkitt-like lymphoma, DLBCL, Genentech, Rituxan, Rituximab
Rituximab plus chemotherapy is approved by FDA for pediatric cancer indications
March 2022: The Food and Drug Administration has approved rituximab (Rituxan, Genentech, Inc.) in conjunction with chemotherapy for CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma..
Atezolizumab, Genentech, NSCLC, Tecentriq, Ventana Medical Systems, VENTANA PD-L1
Atezolizumab is approved by FDA as adjuvant treatment for non-small cell lung cancer
Nov 2021: The Food and Drug Administration has approved atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment in patients with stage II to IIIA non-small cell lung cancer (NSCLC) whose tumours contain PD-L1 expression o..